Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Dovedi, Simon J; Cheadle, Eleanor J; Popple, Amy L; Poon, Edmund; Morrow, Michelle; Stewart, Ross; Yusko, Erik C; Sanders, Catherine M; Vignali, Marissa; Emerson, Ryan O; Robins, Harlan S; Wilkinson, Robert W; Honeychurch, Jamie; Illidge, Timothy M

Dovedi, Simon J; Cheadle, Eleanor J; Popple, Amy L; Poon, Edmund; Morrow, Michelle; Stewart, Ross; Yusko, Erik C; Sanders, Catherine M; Vignali, Marissa; Emerson, Ryan O; Robins, Harlan S; Wilkinson, Robert W; Honeychurch, Jamie; Illidge, Timothy M.

Afiliação

Dovedi SJ; Targeted Therapy Group, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, Christie Hospital, Manchester Academic Health Sciences Centre, United Kingdom. DovediSi@MedImmune.com Tim.Illidge@manchester.ac.uk.
Cheadle EJ; MedImmune Ltd., Granta Park, Cambridge, United Kingdom.
Popple AL; Targeted Therapy Group, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, Christie Hospital, Manchester Academic Health Sciences Centre, United Kingdom.
Poon E; Targeted Therapy Group, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, Christie Hospital, Manchester Academic Health Sciences Centre, United Kingdom.
Morrow M; MedImmune Ltd., Granta Park, Cambridge, United Kingdom.
Stewart R; MedImmune Ltd., Granta Park, Cambridge, United Kingdom.
Yusko EC; MedImmune Ltd., Granta Park, Cambridge, United Kingdom.
Sanders CM; Adaptive Biotechnologies, Seattle, Washington.
Vignali M; Adaptive Biotechnologies, Seattle, Washington.
Emerson RO; Adaptive Biotechnologies, Seattle, Washington.
Robins HS; Adaptive Biotechnologies, Seattle, Washington.
Wilkinson RW; Fred Hutchinson Cancer Research Center, Seattle, Washington.
Honeychurch J; MedImmune Ltd., Granta Park, Cambridge, United Kingdom.
Illidge TM; Targeted Therapy Group, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, Christie Hospital, Manchester Academic Health Sciences Centre, United Kingdom.

Clin Cancer Res ; 23(18): 5514-5526, 2017 Sep 15.

Article em En | MEDLINE | ID: mdl-28533222

Assuntos

Antineoplásicos Hormonais/farmacologia; Linfócitos do Interstício Tumoral/efeitos dos fármacos; Linfócitos do Interstício Tumoral/imunologia; Linfócitos do Interstício Tumoral/efeitos da radiação; Neoplasias/imunologia; Neoplasias/patologia; Receptor de Morte Celular Programada 1/antagonistas & inibidores; Subpopulações de Linfócitos T/efeitos dos fármacos; Subpopulações de Linfócitos T/imunologia; Subpopulações de Linfócitos T/efeitos da radiação; Animais; Linhagem Celular Tumoral; Terapia Combinada; Citocinas/metabolismo; Modelos Animais de Doenças; Humanos; Linfócitos do Interstício Tumoral/metabolismo; Camundongos; Neoplasias/metabolismo; Neoplasias/terapia; Receptor de Morte Celular Programada 1/metabolismo; Radioterapia; Receptores de Antígenos de Linfócitos T alfa-beta/metabolismo; Taxa de Sobrevida; Subpopulações de Linfócitos T/metabolismo; Ensaios Antitumorais Modelo de Xenoenxerto

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Subpopulações de Linfócitos T / Linfócitos do Interstício Tumoral / Antineoplásicos Hormonais / Receptor de Morte Celular Programada 1 / Neoplasias Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google